Cosentyx Dosing for Psoriatic Arthritis
For psoriatic arthritis, the recommended Cosentyx (secukinumab) dosing is 150 mg every 4 weeks after a loading regimen, with the option to escalate to 300 mg every 4 weeks if disease activity persists.
Initial Dosing Strategy
The standard approach depends on skin involvement:
Patients WITHOUT concomitant moderate-to-severe plaque psoriasis: Start with 150 mg at weeks 0,1,2,3, and 4, followed by 150 mg every 4 weeks 1, 2
Patients WITH concomitant moderate-to-severe plaque psoriasis: Use the higher plaque psoriasis dosing of 300 mg at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks 1, 2
Anti-TNFα inadequate responders: The recommended dose is 300 mg from the start 1
When to Escalate to 300 mg Every 4 Weeks
If a patient continues to have active psoriatic arthritis despite 150 mg dosing, escalate to 300 mg every 4 weeks 1, 2. This dose escalation strategy is supported by:
- Clinical trial data showing that approximately 52% of patients required dose escalation during long-term treatment 3
- Evidence that dose escalation from 150 mg to 300 mg resulted in decreased proportions of ACR and PASI non-responders within 24-32 weeks after escalation 3
- Superior efficacy demonstrated with 300 mg versus 150 mg dosing in multiple trials 4
Clinical Evidence Supporting This Approach
The 300 mg dose has consistently shown greater efficacy than 150 mg across multiple domains:
- ACR responses: At 5 years, ACR20 was achieved in 74% with 300 mg versus 70% with 150 mg; ACR50 in 52% versus 43%; and ACR70 in 32% versus 29% 3
- Safety profile: The higher 300 mg dose appears equally safe as 150 mg 4
- Sustained efficacy: Both doses maintain clinical improvements through 5 years of treatment 3, 5
Important Caveats
- Loading regimen is critical: The weekly dosing for the first month (weeks 0,1,2,3, and 4) establishes therapeutic levels rapidly 2
- Consider discontinuation: If there is no response after 16 weeks of treatment, discontinuation should be considered 1
- Alternative IV dosing: For patients requiring intravenous administration, 1.75 mg/kg every 4 weeks (with or without a 6 mg/kg loading dose) is FDA-approved, though total doses should not exceed 300 mg per infusion 2, 6, 7
The evidence clearly supports starting most PsA patients at 150 mg every 4 weeks, but maintaining flexibility to escalate to 300 mg based on clinical response, particularly in anti-TNF inadequate responders or those with significant skin involvement.